First-In-Human Study on Pharmacokinetics, Safety, and Tolerability of Single and Multiple Escalating Doses of Hepenofovir, a Novel Hepatic Targeting Prodrug of Tenofovir in Healthy Chinese Subjects

Objective: Hepenofovir, a novel hepatic targeting prodrug of tenofovir, has been developed for the treatment of chronic hepatitis B (CHB). This is a first-in-human study to evaluate the pharmacokinetics (PK) and tolerability of single and multiple escalating doses of hepenofovir in healthy Chinese s...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Hong, Gao, Lei, Lou, Jinfeng, Wu, Min, Chen, Hong, Yang, Lizhi, Liu, Jingrui, Zhu, Xiaoxue, Li, Xiaojiao, Li, Cuiyun, Wang, Meng, Liu, Chengjiao, Guo, Weibo, Wang, Yuan, Gao, Zhongqiang, Han, Lei, Wang, Daidi, Jin, Weili, Ding, Yanhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9161552/
https://www.ncbi.nlm.nih.gov/pubmed/35662718
http://dx.doi.org/10.3389/fphar.2022.873588

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9161552/
https://www.ncbi.nlm.nih.gov/pubmed/35662718
http://dx.doi.org/10.3389/fphar.2022.873588

Ejemplares similares